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Abstract
Biomarker data is often subject to limits of quantification and/or limits of detection.
Statistically, this corresponds to left- or interval-censoring. To be able to associate a
censored time-to-event endpoint to a biomarker covariate, the R package SurvRegCen-
sCov provides software for Weibull regression for a right-censored endpoint, one interval-
censored, and an arbitrary number of non-censored covariates. Furthermore, the package
provides functions to estimate canonical parameters from censored samples based on sev-
eral distributional assumptions, and a function to switch between different parametriza-
tions used in R for Weibull regression. We illustrate the new software by applying it
to assess Prentice’s criteria for surrogacy in data simulated from a randomized clinical
registration trial.
Keywords: Weibull Regression, censored covariate, limit of detection, biomarker, surrogacy,
Prentice’s criteria, R.
1. Introduction
In survival analysis, we typically seek to analyze the association between a collection of covari-
ates and a time-to-event endpoint. Regression models, such as Cox or parametric regression,
are well-developped and available for the common situation where the endpoint is right- or
even interval-censored, see e.g.
”
Klein and Moeschberger (2003). However, when analyzing
biomarkers it may happen that also one or more covariates are censored, typically left-censored
at a limit of detection (LOD) c which is given by assay sensitivity, i.e., the researcher only
knows that the actual value of a biomarker, say, is ≤ c, but does not know the exact mea-
surement. We refer to Arunajadai and Rauh (2012) and Bernhardt, Wang, and Zhang (2014)
for overviews on methods how to handle left-censored data, to Langohr, Gomez, and Muga
(2004) for the description of a parametric survival regression model with a censored discrete
covariate, and to Armbruster and Pry (2008) for a discussion of the different types of limits
that appear in generation of biomarker data.
Bernhardt et al. (2014) also provides a discussion of “traditional” approaches to treat left-
censoring in covariates, namely complete case analysis or various imputation methods, e.g.,
replacing a left-censored observation by the limit of detection c itself, by c/2, or c/
√
2. As
long as the censoring does not depend on the survival time, removing observations below c
still yields consistent estimates, however, at the cost of reduced efficiency (Bernhardt et al.
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2014, Proposition 1). Arunajadai and Rauh (2012) show that na¨ıve implementation methods
typically yield potentially hugely biased estimates and they recommend that, since there are
no specific sets of conditions under which imputation methods can be guaranteed to perform
well, these methods should generally not be used. In addition to their empirical inferiority,
there is also not much theoretical justification for these na¨ıve approaches. c/2 could be seen
as taking the mean of a Uniform random variable on [0, c], but the motivation of c/
√
2 is not
clear.
To correctly account for the nature of the data, i.e., censored time-to-event endpoint with
a left-censored covariate, Sattar, Sinha, and Morris (2012) derive and maximize a likelihood
function assuming a Weibull distribution for the time-to-event endpoint and one left-censored
covariate. To be able to incorporate the latter in a fully parametric survival regression model,
a fully-known distribution for the left-censored covariate has to be imposed. In Sattar et al.
(2012), a Normal distribution is assumed for the left-censored covariate. As we are in a fully
parametric model, statistical inference can be based on standard likelihood theory. So far, no
publicly available software is available that provides estimates and inference in this model.
SurvRegCensCov closes this gap. Our implementation extends the work of Sattar et al. (2012)
with respect to the following features:
• We allow for estimation of the shape parameter γ of the Weibull distribution, which
was set to 1 in the simulations in Sattar et al. (2012).
• As we outline in our example in Section 4, in applications the incompletely observed
covariate sometimes is not only left- but rather interval-censored. Our implementation
allows for that data structure.
• In the example we use for illustration, the regression model involves at least one more
non-censored covariate in addition to the censored covariate. We thus extend the code
described in Sattar et al. (2012) to be able to take into account an arbitrary num-
ber of non-censored covariates. As a matter of fact, no non-censored covariate, i.e.,
a Weibull regression model involving only the censored covariate, can also be handled
using SurvRegCensCov.
• The likelihood function set up to accommodate the Weibull regression model necessitates
for every censored covariate observation computation of a rather involved integral, see
Section 3. Sattar et al. (2012) suggest to use Simpson’s 1/3 rule for computation of
these integrals, implying (if we understand their approach correctly) that certain tuning
parameters have to be selected. We proceed differently and omit this choice of tuning
parameters, see Section 3.
• Finally, we provide some functions to easily switch between different parametrizations
used for Weibull regression models.
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1.1. About this document
The package is available from the Comprehensive RArchive Network at http://CRAN.R-project.
org/package=SurvRegCensCov (R Core Team 2014).
This document was created using Sweave (Leisch 2002), LATEX (Knuth 1984; Lamport 1994),
and R (R Core Team 2014). This means that all of the code has been checked by R.
2. Methods
2.1. Two-sample inference for censored Normal samples
Lynn (2001) describes maximum likelihood estimation for one left-censored sample based on
parametric assumptions. proc lifereg in SAS and the R package fitdistrplus (Delignette-
Muller, Pouillot, Denis, and Dutang 2013) implement that methodology for a large catalogue
of distributions to choose from. proc lifereg also allows for inference based on two sam-
ples, for a variety of distributions. In the Normal case proc lifereg implicitly assumes
that the variances in the two groups are identical. However, in our applications we typi-
cally do not want to entertain that restriction, and that is why we have added the function
NormalMeanDiffCens to SurvRegCensCov. It allows for inference from two independent
interval-censored samples assumed to come from Normal distributions with different means
and variances. Note that the default setting for the t.test function, i.e., inference from two
completely observed Normal samples, is indeed as well var.equal = FALSE. We illustrate the
application of NormalMeanDiffCens in Section 4.
In addition to a function for the two-sample Normal case, SurvRegCensCov also provides
a function (ParamSampleCens) to estimate canonical parameters from one sample, for the
Normal, Logistic, Gamma, and Weibull distribution. Note that the function fitdistcens in the
package fitdistrplus (Delignette-Muller et al. 2013) offers similar functionality.
2.2. Weibull regression model with a censored covariate - the model
Define a triple (T, δ,X), where T denotes the follow-up time, δ is the censoring indicator, and
X ∈ Rd is a (time-invariant) vector of baseline covariates. The actual survival time is Z and
the censoring time C, so that we observe T = min{Z,C} and δ = 1{T ≤ Z}, with 1{·} the
indicator function. The survival time Z is assumed to be conditionally independent given X,
i.e., the censoring is supposed to be non-informative. Sattar et al. (2012) then assume that
Z follows a Weibull distribution with shape parameter γ and scale parameter λ, so that the
density and hazard function of Z are defined as
f0(z) = λγz
γ−1 exp(−λzγ) h0(z) = λγzγ−1. (1)
This is the parametrization used by Klein and Moeschberger (2003, Chapter 12). Note that
R’s dweibull function uses another parametrization, namely
f∗0 (z) = (a/b)(z/b)
a−1 exp
(
−(z/b)a
)
h∗0(z) = (a/b)(z/b)
a−1,
so that the reparametrization is γ = a, λ = b−a. Yet another parametrization is used by the
survreg function in survival (Therneau 2013; Therneau and Grambsch 2000), see (2).
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Using Parametrization (1) to set up a Weibull regression, we then assume that the hazard
function, for a given covariate vector X and a corresponding vector β of regression parameters,
can be written as
h(z|X) = exp(β>X)h0(z)
= exp(β>X)λγzγ−1
=: λ?γzγ−1.
The last equality shows that we model the scale parameter λ? = λ exp(β>X) using a base scale
λ and covariates. The coefficients expβ feature the proportional hazards property, i.e., can be
interpreted as hazard ratios. On the other hand, survreg embeds Weibull regression in the
framework of a more general accelerated failure time model and its output provides estimates
for log(σ) (denoted Log(scale)), −µ/σ (Intercept), and the regression parameters α. The
reparametrization from (1) is
γ = σ−1, λ = exp(−µ/σ), β = −α/σ. (2)
In SurvRegCensCov, the function ConvertWeibull takes the output of survreg as input
and transforms parameter estimates to Parametrization (1), thereby allowing to easily switch
from the accelerated failure time to the proportional hazard interpretation. Transformed
confidence intervals, based on applying the δ-rule to survreg’s standard errors (see Klein
and Moeschberger 2003, Section 12.2), are available as well. ConvertWeibull also computes
the “acceleration factor” expα, alternatively called “event time ratio”, see e.g., Carroll (2003)
for how to interpret it. Note that the Weibull distribution is the only parametric family
that allows to set up a regression model that allows for both, a proportional hazard and an
accelerated failure time interpretation.
2.3. Maximum likelihood estimation of parameters
Now assume we have an i.i.d. sample (Ti, δi,Xi), i = 1, . . . , n of observations and want to
estimate the parameter vector (γ, λ, β) based on this data and maximum likelihood. The
corresponding likelihood function for completely observed Xi is, according to Sattar et al.
(2012),
L1(γ, λ, β) =
n∏
i=1
h(Ti|X)δiS(Ti|X)
=
n∏
i=1
f(Ti|X)δiS(Ti|X)1−δi .
For the moment, let us further assume that we observe some of the entries of the first covari-
ate (X11, . . . , X1n) only if it is above the patient-specific LOD ci and that for those values
below ci, we simply use some imputation scheme, typically just impute ci. Then, maximum
likelihood estimates (MLE) based on L1 are in general biased (D’Angelo and Weissfeld 2008;
Sattar et al. 2012). In order to account for X1i potentially being censored, Sattar et al.
(2012) make additional assumptions and modify the likelihood function as follows: First, we
explicitly specify a distribution for X1i by specifying the density fθ, where θ ∈ Rd indicates
the parametrization of f , for d ≥ 1. Note that they assume the same distribution for all ob-
servations. Often, it seems sensible to assume fθ = fµ,σ2 as Normal, maybe after taking the
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logarithm of X1i. Define for each observation the binary random variable Ri := 1{X1i ≥ ci}
that indicates the status of the observation, i.e., whether it is observed or left-censored. The
probability mass function pRi of Ri is a simple Bernoulli distribution with success probability
pii = P (X1i > ci) =
∫∞
ci
fθ(x)dx that X1i is observed.
Klein and Moeschberger (2003, Chapter 3.5) explain how arbitrarily censored data contributes
to the likelihood function when we estimate parameters from a random sample. Sattar et al.
(2012, Formula 2) use this to construct the Weibull regression likelihood function based on
our available data including a left-censored covariate, yielding
L2(γ, λ, β) =
n∏
i=1
(
f(Ti|X)δiS(Ti|X)1−δipRi(ri)fθ(X1i)
)ri ×
(∫ ci
−∞
f(Ti|X)δiS(Ti|X)1−δipRi(ri)fθ(x)dx
)1−ri
.
This likelihood can in general not be written in closed form and has thus to be maximized
numerically. The MLE is defined as
(γ̂, λ̂, β̂) := arg max
(γ,λ,β)∈R2+d
logL2(γ, λ, β).
Extension to interval-censoring and more than one censored covariate is straightforward, but
tedious. The function SurvRegCov in SurvRegCensCov provides standard errors of the esti-
mates (γ̂, λ̂, β̂) based on the observed Fisher information matrix.
3. Implementation
To maximize L2, we use R’s function optim. Note that maximization of L2 is not entirely
straightforward, as for each evaluation of L2 at a given value of the parameter vector (γ, λ, β),
n −∑ni=1Ri integrals have to be numerically computed. As discussed in Section 1, Sattar
et al. (2012) use an approximation rule to compute the integrals, and - if we interpret their
description of implementation correctly - their approach necessitates the choice of the tuning
parameters a, b, h, where [a, b] is the interval the function to be integrated “lives on” and h is
the grid length. In our initial implementation of Sattar et al. (2012)’s approach, the choice of
these parameters might depend on the actual data, i.e., the maximization of the log-likelihood
function potentially needs to be tuned manually for a given dataset. Instead, we simply set
very small values of the function to be integrated to 0. We can then use R’s integrate function
to do the repeated integrations, implying a considerable gain in computational speed without
sacrifying numerical accuracy of the resulting estimates. The modification also implies that
the maximization of the log-likelihood function in our SurvRegCensCov is fully automatic
and does not necessitate the choice of tuning parameters.
To compute the Hessian matrix of the log-likelihood function we use the package numDeriv
(Gilbert and Varadhan 2012). The latter generally provides more accurate computations of
derivatives in complex problems than optim.
The function SurvRegCens in SurvRegCensCov implements maximization of L2, and provides
standard statistical inference for the resulting parameter estimate (γ̂, λ̂, β̂). In addition to this
main function of the package, SurvRegCensCov provides ConvertWeibull to reparametrize
the output of survreg, WeibullReg does these two steps in one function, and WeibullDiag
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constructs a diagnostic plot to visually check the adequacy of the Weibull distribution for
survival data with respect to one nominal covariate.
4. Examples
Sattar et al. (2012) illustrate Weibull regression with a left-censored covariate and no com-
pletely observed covariate using the Genetic and Inflammatory Marker of Sepsis (GenIMS)
study (Yende, D’Angelo, and et al. 2008). The interest was to associate the right-censored
endpoint to some cytokine levels which were subject to a uniform LOD c.
4.1. Surrogacy
Our incentive to implement the methodology came from another application: So far, registra-
tional studies for new drugs in chronic lymphoid leukemia (CLL) typically used progression-
free survival (PFS) as their primary endpoint. With the advent of ever more potent therapies
in this disease and luckily for patients, PFS is getting longer and longer, especially in those
patients that are considered “fit” for aggressive chemotherapy. As an example, the patients
in the treatment arm of the CLL8 study (Hallek, Fischer, and et al. 2010), a randomized
trial in first-line CLL patients, were seen with a median PFS of 57 months (Fisher, Bahlo,
and et al. 2012). As this improvement in PFS continues, clinical studies with PFS as an
endpoint become infeasible and surrogate endpoints for PFS are sought. In addition, several
treatment regimens are entering the CLL landscape which tackle the disease from different
angels and are or will be approved in the near future. In order to establish efficacy of these
new therapies, or even combinations between them, “early” measurable endpoints that replace
the ever growing PFS are needed. Such a potential early measurable and surrogacy candidate
is minimal residual disease (MRD, Bottcher, Ritgen, and et al. 2012), a continuous endpoint
that basically counts the number of cancerous cells left in the body after therapy. MRD
can be measured either by IGH polymerase chain reaction (PCR) or flow cytometry. The
latter method was used in CLL8 and exhibited a sensitivity of c := 10−4, i.e., some of the
measurements are indeed left-censored at c.
Note that MRD is not a biomarker in the strict sense, but rather an endpoint that measures
effect of therapy after patient has undergone treatment. However, left-censoring often occurs
when analyzing biomarker data, so that our new software is applicable in a much broader
sense than to assess surrogacy only.
The CLL11 study (Goede, Fischer, and et al. 2014) established superiority of a 2nd generation
CD20 antibody, obinutuzumab, over rituximab, a 1st generation antibody. In this trial, MRD
was measured using PCR via a patient-specific assay. Furthermore, as is typical for small
MRD values, the exact value can often not be measured, so that the labs provided a lower and
upper limit of detection in these cases, i.e., some of the measurements were in fact genuinely
interval-censored. As a consequence, in order to establish surrogacy based on CLL11 data,
we indeed needed to extend the setup in Sattar et al. (2012) to allow for interval-censored
data.
To formally establish surrogacy, the first step is typically to assess what is called “Prentice’s
criteria” (Prentice 1989). The goal is to show that the hazard for PFS is independent of
treatment, conditional on the surrogate variable MRD. In order to do so, a regression model
with PFS as endpoint and MRD as well as treatment as covariates has to be set up. Prentice’s
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criteria can be considered met if in such a model, MRD is associated with the endpoint
and captures all the effect of the treatment, i.e., the latter is not anymore associated to
the endpoint. Thus, Prentice’s criteria is typically regarded as fulfilled if treatment is not
significant anymore at a pre-specififed significance level in this regression model and has a
small effect estimate.
In Bottcher et al. (2012), MRD was discretized in three categories using cutoffs 10−4 and 10−2.
Discretization might make sense clinically, but from a statistical point of view it is well-known
that by discretization we loose up to 1/3 of the information in a given continuous variable
(Lagakos 1988). So one of our goals with implementing SurvRegCensCov was to assess
Prentice’s criteria for the CLL11 study using the full MRD information, i.e., considering the
latter a continuous - but interval-censored - covariate in a Weibull regression model.
4.2. Imitating the CLL11 study
Goede et al. (2014) is the first paper on CLL11 that reports clinical results and only contains
very high-level MRD results. No detailed analysis of MRD in CLL11 has been published yet
and we are thus not able to illustrate SurvRegCensCov using original CLL11 data, although
this study actually initiated our work and motivated the extensions discussed above.
To understand the features of our new and two potential traditional approaches in the context
of CLL11, we instead simulate data with similar properties than the one in the rituximab (R,
n = 226) and obinutuzumab (O, n = 221) treatment arms in CLL11 to illustrate SurvReg-
CensCov. To this end, we first explored the MRD data. As is typical for biomarker data,
original MRD measurements were right-skewed, so that we used log(MRD) in our model.
The transformed measurements nicely followed a Normal distribution. Since log(MRD) is
a continuous interval-censored variable, we used ParamSampleCens to estimate µ and σ of
the assumed Normal distribution, in each treatment arm separately. Applying the function
SurvRegCens we finally estimated the canonical parameters λ, γ and the regression coefficients
βtmt, βMRD corresponding to treatment and log(MRD) in our Weibull regression model. We
end up with eight estimated parameters µ̂R, σ̂R, µ̂O, σ̂O, λ̂, γ̂, β̂tmt and β̂MRD based on CLL11
data. In addition, we also determined the proportion of censored MRD observations in each
treatment arm. Using these estimated parameters and the assumptions of Normality of the
density fθ of the censored covariate and Weibull distributed PFS times, we can simulate right-
censored PFS times. Contrasting these simulated PFS times to the original CLL11 data, we
get strikingly similar Kaplan-Meier estimates.
To mimick CLL11 data (which we are not able to show at this point) in a small simulation
study, we thus sufficiently varied the eight parameters above that define our model, so that
no conclusion on the true nature of CLL11 data is possible. Specifically, we assumed µR =
−1.5, σR = 1.5, µO = −3.5, σO = 1.5, λ = 0.75, γ = 3.1, βtmt = 0 and βMRD = 0.7 as well as
proportions of 0.05 and 0.35 of left-censored MRD values as well as a sample size of n = 200
in each simulated arm. We note that the higher proportion of left-censored MRD values in
the obinutuzumab arm is indicative of the higher efficacy of that treatment. We deliberately
choose the model to have no treatment effect, as this corresponds to the “ideal” situation
when indeed MRD is a complete surrogate for PFS. Since in our simulation study we compare
Weibull regression with a censored covariate to Weibull and Cox regression where we impute
the censored observations by the LOD, we only left-censor MRD in our simulation. This
implies that we can compare the newly implemented to the latter more standard methods
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with imputation at the LOD. MRD values were left-censored at the quantiles corresponding
to the empirical censoring proportions 0.05 and 0.35 in CLL11.
To illustrate SurvRegCens the chunk below provides its model output received from estimat-
ing the model based on the first simulated sample and Figure 1 provides the Kaplan-Meier
estimates of this simulated sample:
R> WRmod1 <- SurvRegCens(formula = formula(Surv(time, event) ~
+ Surv(time = mrd.low, time2 = mrd.up, type = "interval2") +
+ tmt.df), data = data.frame(time, event, mrd.low, mrd.up,
+ tmt.df), Density = DensityCens, initial = initial,
+ namCens = "mrd", trace = 0)
R> summary(WRmod1)
Weibull regression for a right-censored response with an interval-censored covariate
Call:
SurvRegCens(formula = formula(Surv(time, event) ~ Surv(time = mrd.low,
time2 = mrd.up, type = "interval2") + tmt), data = data.frame(time,
event, mrd.low, mrd.up, tmt), Density = DensityCens, initial = initial,
namCens = "mrd", trace = 0)
Coefficients:
Estimate Std. Error CI.low CI.up p-value
lambda 0.74595 0.08455 0.58024 0.91166 NA
gamma 2.98008 0.16942 2.64802 3.31213 NA
tmt 0.14092 0.16852 -0.18937 0.47121 0.403
mrd 0.67344 0.06010 0.55565 0.79122 <2e-16
AIC: 2290.1
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MRD assumed to be Normal and PFS assumed to follow a Weibull distribution.
control arm (rituximab in CLL11)
experimental arm (obinutuzumab in CLL11)
Figure 1: Kaplan-Meier estimates of PFS for first simulated sample.
The model is well able to estimate the parameters of interest and the estimated coefficient
of treatment is indeed close to 0, or the hazard ratio exp(Estimator) close to 1, and non-
significant at α = 0.05. The MRD covariate is specified as interval-censored using the coding
for type = interval2 in Surv (Therneau 2013):
R> head(data.frame(mrd.low, mrd.up))
mrd.low mrd.up
1 -1.5124 -1.5124
2 -0.7509 -0.7509
3 -1.7824 -1.7824
4 -1.9962 -1.9962
5 -2.6862 -2.6862
6 NA -3.9673
The estimated parameters of log(MRD) in each treatment arm are
R> NormalMeanDiffCens(censdata1 = mrd.r, censdata2 = mrd.o)
Estimator Std. Error CI.low CI.up p-value
mu1 -1.532 0.10429 -1.737 -1.328 <2e-16
mu2 -3.358 0.10007 -3.554 -3.162 <2e-16
sigma1 1.468 0.07707 1.317 1.619 1.2e-09
sigma2 1.329 0.08474 1.163 1.496 1e-04
Mean difference delta 1.826 0.14454 1.542 2.109 <2e-16
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Again, the underlying true parameters are accurately estimated. However, note that in our
model in Section 2.3 we assume the same density fθ for the censored covariate for all obser-
vations, so that to estimate WRmod1 above we used DensityCens defined according to
R> res1 <- ParamSampleCens(censdata = rbind(mrd.r, mrd.o), dist = "normal")
R> res1$coeff
Estimator Std. Error CI.low CI.up p-value
Mu -2.467 0.08774 -2.639 -2.295 <2e-16
Sigma 1.712 0.06975 1.576 1.849 <2e-16
R> DensityCens <- function(value, res = res1){return(dnorm(value,
+ mean = res$coeff[1, 1] , sd = res$coeff[2, 1]))}
4.3. Simulation results
We generated M = 1000 “CLL11 like” trials using the parameters above and for each simula-
tion we estimated three regression models for PFS and explanatory variables treatment and
log(MRD):
• Weibull regression using the function survreg in survival, where left-censored MRD
values were considered to be actual measurements, i.e., we impute the lower limit of
detection as an actual MRD value.
• Cox regression with the same imputation strategy, using the function coxph in survival.
• Weibull regression assuming normally distributed log(MRD), correctly accounting for
the censoring of MRD via the function SurvRegCensCov.
As discussed in Section 1, imputing the limit of detection for left-censord values is common in
applications. Figure 2 provides boxplots of the 1000 estimated parameters whereas Table 1
displays the bias of each method in estimating the Weibull and/or regression parameters.
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Weibull regression, LOD imputation for left−censored MRD
Cox regression, LOD imputation for left−censored MRD
Weibull regression, correctly accounting for left−censored MRD
λ^ γ^ β^tmt β^MRD
Figure 2: Boxplots of estimated parameters in 1000 simulations.
λ̂ γ̂ β̂tmt β̂MRD
True parameter value we simulated from 0.75 3.1 0 0.7
Bias Weibull regression, correctly accounting for left-censored MRD 0.0069 0.0231 -0.0060 0.0046
Bias Weibull regression, LOD imputation for left-censored MRD 4.7 5.6 4.8 8.5
Bias Cox regression, LOD imputation for left-censored MRD 1.3 10.3
Table 1: Bias for Weibull regression with censored covariate and relative bias for imputation
methods. Rows 2 and 3 are factors by which Row 1 is multiplied to get the bias of the other
methods. Biases for β̂tmt were negative for all three methods.
We find that absolute bias is moderate for all three methods, but that clearly Weibull re-
gression correctly accounting for the left-censoring of MRD performs best. This remains true
when we look at the mean-squared error in Table 2. Finally, in an analysis of surrogacy we
are interested in testing the null hypothesis of no treatment effect in a hypothesis test. As we
simulated assuming that βtmt = 0, by counting how often in our simulations a test for this
hypothesis at a significance level of α = 0.05 rejects we get an empirical assessment how well
each method keeps the probability of a type I error. Weibull regression correctly accounting
for left-censoring yielded a proportion of 0.05 rejected null hypothesis for the treatment re-
gression parameter, Weibull regression with LOD imputation 0.062, and Cox regression with
LOD imputation 0.059. Thus the maximum likelihood estimate exactly keeps the probability
of a type I error, whereas the two approximate methods slightly inflate it.
5. Discussion
Biomarker measurements with lower and/or upper limit of detection are common in applied
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λ̂ γ̂ β̂tmt β̂MRD
True parameter value we simulated from 0.75 3.1 0 0.7
MSE Weibull regression, correctly accounting for left-censored MRD 0.00005 0.00053 0.00004 0.00002
MSE Weibull regression, LOD imputation for left-censored MRD 21.9 31.4 22.8 72.7
MSE Cox regression, LOD imputation for left-censored MRD 1.8 105.9
Table 2: Mean-squared error for Weibull regression with censored covariate and relative bias
for imputation methods. Rows 2 and 3 are factors by which Row 1 is multiplied to get the
MSE of the other methods.
statistics. Motivated by a concrete application in a large clinical registration study, namely to
establish surrogacy of MRD for PFS in CLL, we implemented an extension to the method ini-
tially proposed in Sattar et al. (2012) and collected the code in the package SurvRegCensCov.
Bernhardt et al. (2014) note that maximizing L2(γ, λ, β) can be extremely slow, due to the
multiple integrals that need to be evaluated. Computation of the maximizer is indeed not
immediate, but still sufficiently efficient in a typical application.
In our simulation, assuming that proportions of 0.05 and 0.35 of observations of the censored
covariate were actually left-censored, we found that SurvRegCensCov delivers estimates with
lower bias and MSE compared to the traditional methods. The latter also slightly inflated the
probability of a type I error for a hypothesis test on the regression parameter for treatment.
However, bias for the traditional methods was still moderate. Nevertheless, the advantage of
the MLE increases once more values of X1 are in fact censored, once they are also interval-
and not only left-censored, and in case we analyze less observations.
Potential extensions of our implementation are observation-specific assumptions for fθ: In our
example, that would enable to e.g., assume different densities for the censored covariate in
each treatment group. However, as the bias of estimated parameters is already very small with
the assumption of the same density for all observations, we do not anticipate a large gain by
that generalization in typical setups. Other parametric assumptions than Weibull for Z and
Normal for X1 are straightforward to implement. SurvRegCensCov allows for one censored
covariate only. Methodologically, extension to more censored covariates is straightforward,
however, the number of integrals to be computed to evaluate the corresponding maximum
likelihood function would substantially increase, slowing down computations.
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